{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T02:56:22Z","timestamp":1790996182786,"version":"4.1.0"},"reference-count":203,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T00:00:00Z","timestamp":1738108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T00:00:00Z","timestamp":1738108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s11523-024-01122-4","type":"journal-article","created":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T09:26:40Z","timestamp":1738142800000},"page":"247-267","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Multiple Myeloma: Improved Outcomes Resulting from a Rapidly Expanding Number of Therapeutic Options"],"prefix":"10.1007","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-3066-2447","authenticated-orcid":false,"given":"Sarah","family":"Mettias","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1213-2652","authenticated-orcid":false,"given":"Adam","family":"ElSayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2397-8265","authenticated-orcid":false,"given":"Jonathan","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1587-6104","authenticated-orcid":false,"given":"James R.","family":"Berenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,29]]},"reference":[{"issue":"1","key":"1122_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21830","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12\u201349. https:\/\/doi.org\/10.3322\/caac.21830.","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"1122_CR2","doi-asserted-by":"publisher","first-page":"3384","DOI":"10.3324\/haematol.2023.282905","volume":"108","author":"A McCurdy","year":"2023","unstructured":"McCurdy A, Seow H, Pond GP, Gayowsky A, Chakraborty R, Visram A, et al. Cancer-specific mortality in multiple myeloma: a population-based retrospective cohort study. Haematologica. 2023;108(12):3384\u201391. https:\/\/doi.org\/10.3324\/haematol.2023.282905.","journal-title":"Haematologica"},{"issue":"11","key":"1122_CR3","doi-asserted-by":"publisher","first-page":"3102","DOI":"10.1002\/ijc.33135","volume":"147","author":"Y Usui","year":"2020","unstructured":"Usui Y, Ito H, Koyanagi Y, Shibata A, Matsuda T, Katanoda K, et al. Changing trend in mortality rate of multiple myeloma after introduction of novel agents: a population-based study. Int J Cancer. 2020;147(11):3102\u20139. https:\/\/doi.org\/10.1002\/ijc.33135.","journal-title":"Int J Cancer"},{"issue":"5","key":"1122_CR4","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s11523-023-00990-6","volume":"18","author":"S Jew","year":"2023","unstructured":"Jew S, Bujarski S, Regidor B, Emamy-Sadr M, Swift R, Eades B, et al. Clinical outcomes and serum B-cell maturation antigen levels in a real-world unselected population of newly diagnosed multiple myeloma patients. Target Oncol. 2023;18(5):735\u201347. https:\/\/doi.org\/10.1007\/s11523-023-00990-6.","journal-title":"Target Oncol"},{"issue":"3","key":"1122_CR5","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1111\/ejh.13439","volume":"105","author":"M Mohty","year":"2020","unstructured":"Mohty M, Knauf W, Romanus D, Corman S, Verleger K, Kwon Y, et al. Real-world treatment patterns and outcomes in non-transplant newly diagnosed multiple myeloma in France, Germany, Italy, and the United Kingdom. Eur J Haematol. 2020;105(3):308\u201325. https:\/\/doi.org\/10.1111\/ejh.13439.","journal-title":"Eur J Haematol"},{"issue":"17","key":"1122_CR6","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1200\/JCO.19.02515","volume":"38","author":"NS Joseph","year":"2020","unstructured":"Joseph NS, Kaufman JL, Dhodapkar MV, Hofmeister CC, Almaula DK, et al. Long-term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple myeloma. J Clin Oncol. 2020;38(17):1928\u201337. https:\/\/doi.org\/10.1200\/JCO.19.02515.","journal-title":"J Clin Oncol"},{"issue":"14","key":"1122_CR7","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","volume":"376","author":"M Attal","year":"2017","unstructured":"Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017;376(14):1311\u201320. https:\/\/doi.org\/10.1056\/NEJMoa1611750.","journal-title":"N Engl J Med"},{"issue":"2","key":"1122_CR8","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2204925","volume":"387","author":"PG Richardson","year":"2022","unstructured":"Richardson PG, Jacobus SJ, Weller EA, Hassoun H, Lonial S, Raje NS, et al. Triplet therapy, transplantation, and maintenance until progression in myeloma. N Engl J Med. 2022;387(2):132\u201347. https:\/\/doi.org\/10.1056\/NEJMoa2204925.","journal-title":"N Engl J Med"},{"issue":"3","key":"1122_CR9","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/s41375-021-01453-5","volume":"36","author":"M Binder","year":"2022","unstructured":"Binder M, Nandakumar B, Rajkumar SV, Kapoor P, Buadi FK, Dingli D, et al. Mortality trends in multiple myeloma after the introduction of novel therapies in the United States. Leukemia. 2022;36(3):801\u20138. https:\/\/doi.org\/10.1038\/s41375-021-01453-5.","journal-title":"Leukemia"},{"issue":"7","key":"1122_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers15071929","volume":"15","author":"A Chacon","year":"2023","unstructured":"Chacon A, Leleu X, Bobin A. 30 years of improved survival in non-transplant-eligible newly diagnosed multiple myeloma. Cancers. 2023;15(7):1\u201312. https:\/\/doi.org\/10.3390\/cancers15071929.","journal-title":"Cancers"},{"issue":"3","key":"1122_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12020407","volume":"12","author":"V Pinto","year":"2020","unstructured":"Pinto V, Bergantim R, Caires HR, Seca H, Guimar\u00e3es JE, Vasconcelos MH. Multiple myeloma: available therapies and causes of drug resistance. Cancers (Basel). 2020;12(3):1\u201332. https:\/\/doi.org\/10.3390\/cancers12020407.","journal-title":"Cancers (Basel)."},{"issue":"3","key":"1122_CR12","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1182\/blood.V27.3.328.328","volume":"27","author":"JF Holland","year":"1966","unstructured":"Holland JF, Hosley H, Scharlau C, Carbone PP, Frei E, Brindley CO, et al. A controlled trial of urethane treatment in multiple myeloma. Blood. 1966;27(3):328\u201342.","journal-title":"Blood"},{"key":"1122_CR13","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1007\/s12185-023-03579-x","volume":"117","author":"BM Russell","year":"2023","unstructured":"Russell BM, Avigan DE. Immune dysregulation in multiple myeloma: the current and future role of cell-based immunotherapy. Int J Hematol. 2023;117:652\u20139. https:\/\/doi.org\/10.1007\/s12185-023-03579-x.","journal-title":"Int J Hematol"},{"key":"1122_CR14","doi-asserted-by":"publisher","first-page":"36","DOI":"10.14694\/EDBK_159009","volume":"35","author":"SV Rajkumar","year":"2016","unstructured":"Rajkumar SV. Updated diagnostic criteria and staging system for multiple myeloma. ASCO Educ Book. 2016;35:36\u201323. https:\/\/doi.org\/10.14694\/EDBK_159009.","journal-title":"ASCO Educ Book."},{"issue":"12","key":"1122_CR15","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1200\/JCO.2014.59.1636","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. Review International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. J Clin Oncol. 2014;15(12):538\u201348. https:\/\/doi.org\/10.1200\/JCO.2014.59.1636.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1122_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/medsci9010003","volume":"9","author":"SA Padala","year":"2021","unstructured":"Padala SA, Barsouk A, Barsouk A, Rawla P, Vakiti A, Kolhe R, et al. Epidemiology, staging, and management of multiple myeloma. Med Sci. 2021;9(1):1\u201314. https:\/\/doi.org\/10.3390\/medsci9010003.","journal-title":"Med Sci"},{"issue":"3","key":"1122_CR17","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00277-016-2888-3","volume":"96","author":"A Berenson","year":"2017","unstructured":"Berenson A, Vardanyan S, David M, Wang J, Harutyunyan NM, Gottlieb J, et al. Improved clinical outcomes for multiple myeloma patients treated at a single specialty clinic. Ann Hematol. 2017;96(3):441\u20138. https:\/\/doi.org\/10.1007\/s00277-016-2888-3.","journal-title":"Ann Hematol"},{"issue":"2","key":"1122_CR18","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/ejh.13707","volume":"108","author":"CH Blimark","year":"2022","unstructured":"Blimark CH, Vangsted AJ, Klausen TW, Gregersen H, Szabo AG, Hermansen E, et al. Outcome data from >\u200910,000 multiple myeloma patients in the Danish and Swedish national registries. Eur J Haematol. 2022;108(2):99\u2013108. https:\/\/doi.org\/10.1111\/ejh.13707.","journal-title":"Eur J Haematol"},{"issue":"6","key":"1122_CR19","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1097\/CCO.0000000000000792","volume":"33","author":"MD M\u00f6ller","year":"2021","unstructured":"M\u00f6ller MD, Gengenbach L, Graziani G, Greil C, W\u00e4sch R, Engelhardt M. Geriatric assessments and frailty scores in multiple myeloma patients: a needed tool for individualized treatment? Curr Opin Oncol. 2021;33(6):648\u201357. https:\/\/doi.org\/10.1097\/CCO.0000000000000792.","journal-title":"Curr Opin Oncol"},{"issue":"5","key":"1122_CR20","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.3324\/haematol.2019.242958","volume":"105","author":"M Engelhardt","year":"2020","unstructured":"Engelhardt M, Ihorst G, Duque-Afonso J, Wedding U, Sp\u00e4t-Schwalbe E, Goede V, et al. Structured assessment of frailty in multiple myeloma as a paradigm of individualized treatment algorithms in cancer patients at advanced age. Haematologica. 2020;105(5):1183\u20138. https:\/\/doi.org\/10.3324\/haematol.2019.242958.","journal-title":"Haematologica"},{"issue":"1","key":"1122_CR21","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/s41408-023-00843-5","volume":"13","author":"H Mian","year":"2023","unstructured":"Mian H, Wildes TM, Vij R, Pianko MJ, Major A, Fiala MA. Dynamic frailty risk assessment among older adults with multiple myeloma: a population-based cohort study. Blood Cancer J. 2023;13(1):76. https:\/\/doi.org\/10.1038\/s41408-023-00843-5.","journal-title":"Blood Cancer J"},{"issue":"8","key":"1122_CR22","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1158\/1055-9965.EPI-11-0246","volume":"20","author":"MB Cook","year":"2011","unstructured":"Cook MB, McGlynn KA, Devesa SS, Freedman ND, Anderson WF. Sex disparities in cancer mortality and survival. Cancer Epidemiol Biomark Prev. 2011;20(8):1629\u201337. https:\/\/doi.org\/10.1158\/1055-9965.EPI-11-0246.","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"3","key":"1122_CR23","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/bjh.17237","volume":"192","author":"BA Derman","year":"2021","unstructured":"Derman BA, Langerman SS, Maric M, Jakubowiak A, Zhang W, Chiu BCH. Sex differences in outcomes in multiple myeloma. Br J Haematol. 2021;192(3):66\u20139. https:\/\/doi.org\/10.1111\/bjh.17237.","journal-title":"Br J Haematol"},{"issue":"10","key":"1122_CR24","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.clml.2021.04.013","volume":"21","author":"S Bird","year":"2021","unstructured":"Bird S, Cairns D, Menzies T, Boyd K, Davies F, Cook G, et al. Sex differences in multiple myeloma biology but not clinical outcomes: results from 3894 patients in the Myeloma XI trial. Clin Lymphoma Myeloma Leuk. 2021;21(10):667\u201375. https:\/\/doi.org\/10.1016\/j.clml.2021.04.013.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"1122_CR25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/j.1440-0960.2010.00658.x","volume":"52","author":"RS Sun","year":"2010","unstructured":"Sun RS, Sui JF, Chen XH, Ran XZ, Yang ZF, Da Guan W, et al. Detection of CD4 +CD25 +FOXP3 + regulatory T cells in peripheral blood of patients with chronic autoimmune urticaria. Australas J Dermatol. 2010;52(3):15\u20138. https:\/\/doi.org\/10.1111\/j.1440-0960.2010.00658.x.","journal-title":"Australas J Dermatol"},{"issue":"10","key":"1122_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0047077","volume":"7","author":"KR Muthu Raja","year":"2012","unstructured":"Muthu Raja KR, Rihova L, Zahradova L, Klincova M, Penka M, Hajek R. Increased T regulatory cells are associated with adverse clinical features and predict progression in multiple myeloma. PLoS ONE. 2012;7(10):1\u201311. https:\/\/doi.org\/10.1371\/journal.pone.0047077.","journal-title":"PLoS ONE"},{"issue":"1","key":"1122_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/jitc-2019-000286","volume":"8","author":"BA Derman","year":"2020","unstructured":"Derman BA, Zha Y, Zimmerman TM, Malloy R, Jakubowiak A, Bishop MR, et al. Regulatory T-cell depletion in the setting of autologous stem cell transplantation for multiple myeloma: pilot study. J Immunother Cancer. 2020;8(1):1\u20139. https:\/\/doi.org\/10.1136\/jitc-2019-000286.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"1122_CR28","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3324\/haematol.2012.067272","volume":"98","author":"RJP de Magalh\u00e3es","year":"2013","unstructured":"de Magalh\u00e3es RJP, Vidriales MB, Paiva B, Fernandez-Gimenez C, Garc\u00eda-Sanz R, Mateos MV, et al. Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry. Haematologica. 2013;98(1):79\u201386. https:\/\/doi.org\/10.3324\/haematol.2012.067272.","journal-title":"Haematologica"},{"issue":"3","key":"1122_CR29","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.bbmt.2019.12.116","volume":"26","author":"H Schmikla","year":"2020","unstructured":"Schmikla H, de la Mora M, Davis JJ, Montanez LB, Madden EM. Stem cell transplant minimizes insurance coverage-driven outcome disparities for multiple myeloma patients. Biol Blood Marrow Transplant. 2020;26(3):546.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"1122_CR30","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.bbmt.2016.03.008","volume":"22","author":"VR Bhatt","year":"2016","unstructured":"Bhatt VR, Loberiza FR, Schmit-Pokorny K, Lee SJ. Time to insurance approval in private and public payers does not influence survival in patients who undergo hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2016;22(6):1117\u201324. https:\/\/doi.org\/10.1016\/j.bbmt.2016.03.008.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"1122_CR31","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1016\/j.bbmt.2007.09.006","volume":"13","author":"K Rao","year":"2007","unstructured":"Rao K, Darrington DL, Schumacher JJ, Devetten M, Vose JM, Loberiza FR Jr. Disparity in survival outcome after hematopoietic stem cell transplantation for hematologic malignancies according to area of primary residence. Biol Blood Marrow Transplant. 2007;13(12):1508\u201314. https:\/\/doi.org\/10.1016\/j.bbmt.2007.09.006.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"1122_CR32","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/S2352-3026(15)00151-9","volume":"2","author":"SF Huntington","year":"2015","unstructured":"Huntington SF, Weiss BM, Vogl DT, Cohen AD, Garfall AL, Mangan PA, et al. Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot study. Lancet Haematol. 2015;2(10):408\u201316. https:\/\/doi.org\/10.1016\/S2352-3026(15)00151-9.","journal-title":"Lancet Haematol."},{"issue":"4","key":"1122_CR33","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1200\/JCO.19.01564","volume":"38","author":"KR Yabroff","year":"2020","unstructured":"Yabroff KR, Bradley C, Shih YT. Understanding financial hardship among cancer survivors in the United States: strategies for prevention and mitigation. J Clin Oncol. 2020;38(4):292\u2013301. https:\/\/doi.org\/10.1200\/JCO.19.01564.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1122_CR34","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1002\/cam4.2058","volume":"8","author":"DM Jiang","year":"2019","unstructured":"Jiang DM, Chan KKW, Jang RW, Booth C, Liu G, Amir E, et al. Anticancer drugs approved by the food and drug administration for gastrointestinal malignancies: clinical benefit and price considerations. Cancer Med. 2019;8(4):1584\u201393. https:\/\/doi.org\/10.1002\/cam4.2058.","journal-title":"Cancer Med"},{"issue":"12","key":"1122_CR35","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1093\/annonc\/mdw540","volume":"27","author":"SF Huntington","year":"2016","unstructured":"Huntington SF. Cancer-related financial toxicity: beyond the realm of drug pricing and out-of-pocket costs. Ann Oncol. 2016;27(12):2143\u20135. https:\/\/doi.org\/10.1093\/annonc\/mdw540.","journal-title":"Ann Oncol"},{"key":"1122_CR36","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1200\/EDBK_200867","volume":"38","author":"SV Rajkumar","year":"2018","unstructured":"Rajkumar SV. Value and cost of myeloma therapy. ASCO Educ Book. 2018;38:662\u20136. https:\/\/doi.org\/10.1200\/EDBK_200867.","journal-title":"ASCO Educ Book."},{"key":"1122_CR37","unstructured":"The evolving clinical and pharmacoeconomic impact of isatuximab in multiple myeloma management. Value-based cancer care. 2023. https:\/\/www.valuebasedcancer.com\/special-issues\/isatuximab-in-multiple-myeloma-management\/3180-the-evolving-clinical-and-pharmacoeconomic-impact-of-isatuximab-in-multiple-management. Accessed 28 Jan 2024."},{"key":"1122_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canep.2021.101974","volume":"73","author":"H Joshi","year":"2021","unstructured":"Joshi H, Lin S, Fei K, Renteria AS, Jacobs H, Mazumdar M, et al. Multiple myeloma, race, insurance and treatment. Cancer Epid\u00e9mie. 2021;73:1\u20138. https:\/\/doi.org\/10.1016\/j.canep.2021.101974.","journal-title":"Cancer Epid\u00e9mie."},{"issue":"4","key":"1122_CR39","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1177\/2040620713485375","volume":"4","author":"DT Koura","year":"2013","unstructured":"Koura DT, Langston AA. Inherited predisposition to multiple myeloma. Ther Adv Hematol. 2013;4(4):291\u20137. https:\/\/doi.org\/10.1177\/2040620713485375.","journal-title":"Ther Adv Hematol."},{"key":"1122_CR40","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018028530","author":"A Lakshman","year":"2019","unstructured":"Lakshman A, Painuly U, Rajkumar SV, Ketterling RP, Kapoor P, Greipp PT, et al. Impact of acquired del(17p) in multiple myeloma. Blood Adv. 2019. https:\/\/doi.org\/10.1182\/bloodadvances.2018028530.","journal-title":"Blood Adv"},{"issue":"15","key":"1122_CR41","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"PR Greipp","year":"2005","unstructured":"Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blad\u00e9 J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412\u201320. https:\/\/doi.org\/10.1200\/JCO.2005.04.242.","journal-title":"J Clin Oncol"},{"issue":"26","key":"1122_CR42","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol. 2015;33(26):2863\u20139. https:\/\/doi.org\/10.1200\/JCO.2015.61.2267.","journal-title":"J Clin Oncol"},{"key":"1122_CR43","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02614","author":"DA Cairns","year":"2022","unstructured":"Cairns DA, Jos\u00e9 Lahuerta J, Wester R, Bertsch U, Waage A, Zamagni E, et al. Second revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the HARMONY project. J Clin Oncol. 2022;40(29):3406\u201318. https:\/\/doi.org\/10.1200\/JCO.21.02614.","journal-title":"J Clin Oncol"},{"key":"1122_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01162-7","author":"CT Wallington-Beddoe","year":"2021","unstructured":"Wallington-Beddoe CT, Mynott RL. Prognostic and predictive biomarker developments in multiple myeloma. J Hematol Oncol. 2021;14:151. https:\/\/doi.org\/10.1186\/s13045-021-01162-7.","journal-title":"J Hematol Oncol"},{"issue":"8","key":"1122_CR45","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):328\u201346. https:\/\/doi.org\/10.1016\/S1470-2045(16)30206-6.","journal-title":"Lancet Oncol"},{"issue":"S2","key":"1122_CR46","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1097\/HS9.0000000000000243","volume":"3","author":"RG Owen","year":"2019","unstructured":"Owen RG. Minimal residual disease (MRD) in multiple myeloma: prognostic and therapeutic implications (including imaging). Hemasphere. 2019;3(S2):124\u20136. https:\/\/doi.org\/10.1097\/HS9.0000000000000243.","journal-title":"Hemasphere."},{"issue":"1","key":"1122_CR47","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1182\/hematology.2021000230","volume":"2021","author":"AJ Yee","year":"2021","unstructured":"Yee AJ, Raje N. Minimal residual disease in multiple myeloma: why, when, where. Hematology Am Soc Hematol Educ Program. 2021;2021(1):37\u201345. https:\/\/doi.org\/10.1182\/hematology.2021000230.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"7","key":"1122_CR48","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1093\/nar\/22.7.1147","volume":"22","author":"Y Laabi","year":"1994","unstructured":"Laabi Y, Gras MP, Brouet JC, Berger R, Larsen CJ, et al. The BCMA gene, preferentially expressed during B lymphoid maturation, is bidirectionally transcribed. Nucleic Acids Res. 1994;22(7):1147\u201354. https:\/\/doi.org\/10.1093\/nar\/22.7.1147.","journal-title":"Nucleic Acids Res"},{"key":"1122_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms8333","volume":"6","author":"SA Laurent","year":"2015","unstructured":"Laurent SA, Hoffmann FS, Kuhn PH, Cheng Q, Chu Y, Schmidt-Supprian M, et al. \u03b3-Secretase directly sheds the survival receptor BCMA from plasma cells. Nat Commun. 2015;6:1\u201312. https:\/\/doi.org\/10.1038\/ncomms8333.","journal-title":"Nat Commun"},{"issue":"4","key":"1122_CR50","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s11523-021-00821-6","volume":"16","author":"S Bujarski","year":"2021","unstructured":"Bujarski S, Udd K, Soof C, Chen H, Spektor TM, Safaie T, et al. Baseline and changes in serum b-cell maturation antigen levels rapidly indicate changes in clinical status among patients with relapsed\/refractory multiple myeloma starting new therapy. Target Oncol. 2021;16(4):503\u201315. https:\/\/doi.org\/10.1007\/s11523-021-00821-6.","journal-title":"Target Oncol"},{"issue":"2","key":"1122_CR51","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/hon.296","volume":"40","author":"S Bujarski","year":"2022","unstructured":"Bujarski S, Sutanto C, Spektor TM, To J, Swift RA, Green T, et al. Use of serum B-cell maturation antigen levels to predict outcomes for myeloma patients treated with ruxolitinib, lenalidomide and methylprednisolone. Hematol Oncol. 2022;40(2):243\u20138. https:\/\/doi.org\/10.1002\/hon.296.","journal-title":"Hematol Oncol"},{"issue":"9","key":"1122_CR52","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1001\/jama.208.9.1680","volume":"208","author":"R Alexanian","year":"1969","unstructured":"Alexanian R, Haut A, Khan AU, Lane M, McKelvey EM, Migliore PJ, Stuckey WJ Jr, Wilson HE. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA. 1969;208(9):1680\u20135. https:\/\/doi.org\/10.1001\/jama.208.9.1680.","journal-title":"JAMA"},{"issue":"S1","key":"1122_CR53","doi-asserted-by":"publisher","first-page":"37","DOI":"10.5045\/br.2020.S007","volume":"55","author":"SH Jung","year":"2020","unstructured":"Jung SH, Jo JC, Song GY, Ahn SY, Yang DH, Ahn JS, Kim HJ, et al. Frontline therapy for newly diagnosed patients with multiple myeloma. Blood Res. 2020;55(S1):37\u201342. https:\/\/doi.org\/10.5045\/br.2020.S007.","journal-title":"Blood Res."},{"key":"1122_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5772\/intechopen.100849","volume-title":"Recent updates on multiple myeloma","author":"K Ahmed Al-Anazi","year":"2023","unstructured":"Ahmed Al-Anazi K, Alshaibani Z, Kalogianidis P. An update on hematopoietic stem cell transplantation in patients with multiple myeloma. In: Recent updates on multiple myeloma. London: IntechOpen; 2023. p. 1\u201333. https:\/\/doi.org\/10.5772\/intechopen.100849."},{"issue":"3","key":"1122_CR55","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.clml.2022.12.001","volume":"23","author":"AM Khan","year":"2022","unstructured":"Khan AM, Ozga M, Bhatt H, Faisal MS, Ansari S, Zhao Q, et al. Outcomes after salvage autologous hematopoietic cell transplant for patients with relapsed\/refractory multiple myeloma: a single-institution experience. Clin Lymphoma Myeloma Leuk. 2022;23(3):182\u20139. https:\/\/doi.org\/10.1016\/j.clml.2022.12.001.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"Suppl 2","key":"1122_CR56","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/S2152-2650(22)01116-8","volume":"22","author":"LR Reddy","year":"2022","unstructured":"Reddy LR, Kumar L, Veligapudi RM, Konda S. MM-252 A retrospective review of relapsed multiple myeloma post autologous stem cell transplant: data from an Indian tertiary cancer center. Clin Lymphoma Myeloma Leuk. 2022;22(Suppl 2):416. https:\/\/doi.org\/10.1016\/S2152-2650(22)01116-8.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"1122_CR57","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1177\/2040620711413165","volume":"2","author":"W Rehman","year":"2011","unstructured":"Rehman W, Arfons LM, Lazarus HM. The rise, fall and subsequent triumph of thalidomide: lessons learned in drug development. Ther Adv Hematol. 2011;2(5):291\u2013308. https:\/\/doi.org\/10.1177\/2040620711413165.","journal-title":"Ther Adv Hematol."},{"issue":"7933","key":"1122_CR58","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/s41586-022-05333-5","volume":"610","author":"S Ichikawa","year":"2022","unstructured":"Ichikawa S, Flaxman HA, Xu W, Vallavoju N, Lloyd HC, Wang B, et al. The E3 ligase adapter cereblon targets the C-terminal cyclic imide degron. Nature. 2022;610(7933):775\u201382. https:\/\/doi.org\/10.1038\/s41586-022-05333-5.","journal-title":"Nature"},{"issue":"9594","key":"1122_CR59","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1016\/S0140-6736(07)61537-2","volume":"370","author":"T Facon","year":"2007","unstructured":"Facon T, Mary JY, Hulin C, Benboubker L, Attal M, Pegourie B, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99\u201306): a randomised trial. Lancet. 2007;370(9594):1209\u201318. https:\/\/doi.org\/10.1016\/S0140-6736(07)61537-2.","journal-title":"Lancet"},{"issue":"3","key":"1122_CR60","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1182\/blood-2017-07-795047","volume":"131","author":"T Facon","year":"2018","unstructured":"Facon T, Dimopoulos MA, Dispenzieri A, Catalan JV, Belch A, Cavo M, et al. Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. Blood. 2018;131(3):301\u201310. https:\/\/doi.org\/10.1182\/blood-2017-07-795047.","journal-title":"Blood"},{"issue":"7","key":"1122_CR61","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1182\/blood-2009-08-239046","volume":"115","author":"F Gay","year":"2010","unstructured":"Gay F, Hayman SR, Lacy MQ, Buadi F, Gertz MA, Kumar S, et al. Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. Blood. 2010;115(7):1343\u201350. https:\/\/doi.org\/10.1182\/blood-2009-08-239046.","journal-title":"Blood"},{"issue":"6","key":"1122_CR62","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/j.1600-0609.2009","volume":"82","author":"JR Berenson","year":"2009","unstructured":"Berenson JR, Yellin O, Woytowitz D, Flam MS, Cartmell A, Patel R, et al. Bortezomib, ascorbic acid and melphalan (BAM) therapy for patients with newly diagnosed multiple myeloma: an effective and well-tolerated frontline regimen. Eur J Haematol. 2009;82(6):433\u20139. https:\/\/doi.org\/10.1111\/j.1600-0609.2009.","journal-title":"Eur J Haematol"},{"issue":"11","key":"1122_CR63","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1182\/blood.V112.11.650","volume":"112","author":"JF San Miguel","year":"2008","unstructured":"San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, et al. Updated follow-up and results of subsequent therapy in the Phase III VISTA trial: bortezomib plus melphalan\u2013prednisone versus melphalan\u2013prednisone in newly diagnosed multiple myeloma. Blood. 2008;112(11):650. https:\/\/doi.org\/10.1182\/blood.V112.11.650.","journal-title":"Blood"},{"issue":"7","key":"1122_CR64","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1038\/leu.2009.26","volume":"23","author":"CB Reeder","year":"2009","unstructured":"Reeder CB, Reece DE, Kukreti V, Chen C, Trudel S, Hentz J, et al. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia. 2009;23(7):1337\u201341. https:\/\/doi.org\/10.1038\/leu.2009.26.","journal-title":"Leukemia"},{"issue":"5","key":"1122_CR65","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1111\/j.1365-2141.2011.08884.x","volume":"155","author":"JR Berenson","year":"2011","unstructured":"Berenson JR, Yellin O, Chen CS, Patel R, Bessudo A, Boccia RV, et al. A modified regimen of pegylated liposomal doxorubicin, bortezomib and dexamethasone (DVD) is effective and well tolerated for previously untreated multiple myeloma patients. Br J Haematol. 2011;155(5):580\u20137. https:\/\/doi.org\/10.1111\/j.1365-2141.2011.08884.x.","journal-title":"Br J Haematol"},{"issue":"10068","key":"1122_CR66","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","volume":"389","author":"BGM Durie","year":"2017","unstructured":"Durie BGM, Hoering A, Abidi MH, Rajkumar SV, Epstein J, Kahanic SP, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet. 2017;389(10068):519\u201327. https:\/\/doi.org\/10.1016\/S0140-6736(16)31594-X.","journal-title":"Lancet"},{"issue":"2","key":"1122_CR67","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/bjh.15261","volume":"182","author":"EK O\u2019Donnell","year":"2018","unstructured":"O\u2019Donnell EK, Laubach JP, Yee AJ, Chen T, Huff CA, Basile FG, et al. A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. Br J Haematol. 2018;182(2):222\u201330. https:\/\/doi.org\/10.1111\/bjh.15261.","journal-title":"Br J Haematol"},{"issue":"1","key":"1122_CR68","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1182\/blood-2014-03-563759","volume":"124","author":"S Bringhen","year":"2014","unstructured":"Bringhen S, Petrucci MT, Larocca A, Conticello C, Rossi D, Magarotto V, et al. Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. Blood. 2014;124(1):63\u20139. https:\/\/doi.org\/10.1182\/blood-2014-03-563759.","journal-title":"Blood"},{"issue":"9","key":"1122_CR69","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1182\/blood-2012-04-422683","volume":"120","author":"AJ Jakubowiak","year":"2012","unstructured":"Jakubowiak AJ, Dytfeld D, Griffith KA, Lebovic D, Vesole DH, Jagannath S, et al. A phase 1\/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood. 2012;120(9):1801\u20139. https:\/\/doi.org\/10.1182\/blood-2012-04-422683.","journal-title":"Blood"},{"issue":"9","key":"1122_CR70","doi-asserted-by":"publisher","first-page":"162","DOI":"10.3324\/haematol.2014.110395","volume":"99","author":"D Dytfeld","year":"2014","unstructured":"Dytfeld D, Jasielec J, Griffith KA, Lebovic D, Vesole DH, Jagannath S, et al. Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma. Haematologica. 2014;99(9):162\u20134. https:\/\/doi.org\/10.3324\/haematol.2014.110395.","journal-title":"Haematologica"},{"issue":"12","key":"1122_CR71","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/S1470-2045(21)00535-0","volume":"22","author":"F Gay","year":"2021","unstructured":"Gay F, Musto P, Rota-Scalabrini D, Bertamini L, Belotti A, Galli M, et al. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. Lancet Oncol. 2021;22(12):1705\u201320. https:\/\/doi.org\/10.1016\/S1470-2045(21)00535-0.","journal-title":"Lancet Oncol"},{"issue":"6","key":"1122_CR72","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/ajh.26150","volume":"96","author":"N Korde","year":"2021","unstructured":"Korde N, Mastey D, Tavitian E, Mailankody S, Lesokhin A, Hassoun H, et al. Tailored treatment to MRD response: a phase I\/II study for newly diagnosed multiple myeloma patients using high dose twice-weekly carfilzomib (45 and 56 mg\/m2) in combination with lenalidomide and dexamethasone. Am J Hematol. 2021;96(6):193\u20136. https:\/\/doi.org\/10.1002\/ajh.26150.","journal-title":"Am J Hematol"},{"issue":"14","key":"1122_CR73","doi-asserted-by":"publisher","first-page":"4224","DOI":"10.1158\/1078-0432.CCR-18-3642","volume":"25","author":"X Leleu","year":"2019","unstructured":"Leleu X, Fouquet G, Richez V, Guidez S, Duhamel A, Machuron F, et al. Carfilzomib weekly plus melphalan and prednisone in newly diagnosed transplant-ineligible multiple myeloma (IFM 2012\u201303): a phase I trial. Clin Cancer Res. 2019;25(14):4224\u201330. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-3642.","journal-title":"Clin Cancer Res"},{"issue":"18","key":"1122_CR74","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1182\/blood-2018-09-874396","volume":"133","author":"T Facon","year":"2019","unstructured":"Facon T, Lee JH, Moreau P, Niesvizky R, Dimopoulos M, Hajek R, et al. Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma. Blood. 2019;133(18):1953\u201363. https:\/\/doi.org\/10.1182\/blood-2018-09-874396.","journal-title":"Blood"},{"issue":"3","key":"1122_CR75","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s40265-016-0548-5","volume":"76","author":"M Shirley","year":"2016","unstructured":"Shirley M. Ixazomib: First global approval. Drugs. 2016;76(3):405\u201311. https:\/\/doi.org\/10.1007\/s40265-016-0548-5.","journal-title":"Drugs"},{"key":"1122_CR76","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ejca.2018.09.011","volume":"106","author":"MA Dimopoulos","year":"2019","unstructured":"Dimopoulos MA, Grosicki S, J\u0119drzejczak WW, Nahi H, Gruber A, Hansson M, et al. All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. Eur J Cancer. 2019;106:89\u201398. https:\/\/doi.org\/10.1016\/j.ejca.2018.09.011.","journal-title":"Eur J Cancer"},{"issue":"26","key":"1122_CR77","doi-asserted-by":"publisher","first-page":"3616","DOI":"10.1182\/blood.2020008787","volume":"137","author":"T Facon","year":"2021","unstructured":"Facon T, Venner CP, Bahlis NJ, Offner F, White DJ, Karlin L, et al. Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. Blood. 2021;137(26):3616\u201328. https:\/\/doi.org\/10.1182\/blood.2020008787.","journal-title":"Blood"},{"key":"1122_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2023.107324","volume":"131","author":"A Mian","year":"2023","unstructured":"Mian A, Naqvi SAA, Ayaz A, Husnain M, Aljama MA, Mohyuddin GR, et al. Incidence of second primary malignancies in patients with multiple myeloma receiving anti-CD38 monoclonal antibodies: a systematic review and meta-analysis. Leuk Res. 2023;131: 107324. https:\/\/doi.org\/10.1016\/j.leukres.2023.107324.","journal-title":"Leuk Res"},{"issue":"6","key":"1122_CR79","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1056\/NEJMoa1714678","volume":"378","author":"MV Mateos","year":"2018","unstructured":"Mateos MV, Dimopoulos MA, Cavo M, Suzuki K, Jakubowiak A, Knop S, et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med. 2018;378(6):518\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1714678.","journal-title":"N Engl J Med"},{"issue":"10218","key":"1122_CR80","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/S0140-6736(19)32956-3","volume":"395","author":"MV Mateos","year":"2020","unstructured":"Mateos MV, Cavo M, Blade J, Dimopoulos MA, Suzuki K, Jakubowiak A, et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet. 2020;395(10218):132\u201341. https:\/\/doi.org\/10.1016\/S0140-6736(19)32956-3.","journal-title":"Lancet"},{"issue":"4","key":"1122_CR81","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1038\/s41375-021-01488-8","volume":"36","author":"T Facon","year":"2022","unstructured":"Facon T, Cook G, Usmani SZ, Hulin C, Kumar S, Plesner T, et al. Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA. Leukemia. 2022;36(4):1066\u201377. https:\/\/doi.org\/10.1038\/s41375-021-01488-8.","journal-title":"Leukemia"},{"issue":"22","key":"1122_CR82","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","volume":"380","author":"T Facon","year":"2019","unstructured":"Facon T, Kumar S, Plesner T, Orlowski RZ, Moreau P, Bahlis N, et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med. 2019;380(22):2104\u201315. https:\/\/doi.org\/10.1056\/NEJMoa1817249.","journal-title":"N Engl J Med"},{"issue":"7","key":"1122_CR83","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1038\/s41375-023-01936-7","volume":"37","author":"EM Ocio","year":"2023","unstructured":"Ocio EM, Perrot A, Bories P, San-Miguel JF, Blau IW, Karlin L, et al. Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible\/with no immediate intent for autologous stem cell transplantation. Leukemia. 2023;37(7):1521\u20139. https:\/\/doi.org\/10.1038\/s41375-023-01936-7.","journal-title":"Leukemia"},{"key":"1122_CR84","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2400712","author":"T Facon","year":"2024","unstructured":"Facon T, Dimopoulos MA, Leleu XP, Beksac M, Pour L, H\u00e1jek R, et al. Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2024;391:1597\u2013609. https:\/\/doi.org\/10.1056\/NEJMoa2400712.","journal-title":"N Engl J Med"},{"issue":"10","key":"1122_CR85","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S2352-3026(23)00217-X","volume":"10","author":"PM Voorhees","year":"2023","unstructured":"Voorhees PM, Sborov DW, Laubach J, Kaufman JL, Reeves B, Rodriguez C, et al. Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial. Lancet Haematol. 2023;10(10):825\u201337. https:\/\/doi.org\/10.1016\/S2352-3026(23)00217-X.","journal-title":"Lancet Haematol."},{"key":"1122_CR86","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS8056","author":"S Zweegman","year":"2019","unstructured":"Zweegman S, Usmani SZ, Chastain K, Carey J, Ren K, Smith E, et al. Bortezomib, lenalidomide, and dexamethasone (VRd) \u00b1 daratumumab (DARA) in patients with newly diagnosed multiple myeloma for whom transplant is not planned as initial therapy: a multicenter, randomized, phase III study (CEPHEUS). J Clin Oncol. 2019;37(15_suppl):TPS8056. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.TPS8056.","journal-title":"J Clin Oncol"},{"issue":"11","key":"1122_CR87","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.3390\/jcm10112261","volume":"10","author":"SA Holstein","year":"2021","unstructured":"Holstein SA, Suman VJ, Hillengass J, McCarthy PL. Future directions in maintenance therapy in multiple myeloma. J Clin Med. 2021;10(11):2261. https:\/\/doi.org\/10.3390\/jcm10112261.","journal-title":"J Clin Med"},{"issue":"9","key":"1122_CR88","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1182\/blood.v99.9.3163","volume":"99","author":"JR Berenson","year":"2002","unstructured":"Berenson JR, Crowley JJ, Grogan TM, Zangmeister J, Briggs AD, Mills GM, et al. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood. 2002;99(9):3163\u20138. https:\/\/doi.org\/10.1182\/blood.v99.9.3163.","journal-title":"Blood"},{"key":"1122_CR89","doi-asserted-by":"publisher","first-page":"1028571","DOI":"10.3389\/fonc.2023.1028571","volume":"13","author":"Z Zhuang","year":"2023","unstructured":"Zhuang Z, Tian Y, Shi L, Zou D, Feng R, Tian WW, et al. Lenalidomide or bortezomib as maintenance treatment remedy the inferior impact of high-risk cytogenetic abnormalities in non-transplant patients with newly diagnosed multiple myeloma: a real-world multi-centered study in China. Front Oncol. 2023;13:1028571. https:\/\/doi.org\/10.3389\/fonc.2023.1028571.","journal-title":"Front Oncol"},{"issue":"5","key":"1122_CR90","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1007\/s00277-023-05148-y","volume":"102","author":"T Xu","year":"2023","unstructured":"Xu T, Yang Y, Li J, Xu J, Wang W, Wang Y, et al. Real world outcomes of lenalidomide or bortezomib maintenance in patients with multiple myeloma not undergoing stem cell transplantation. Ann Hematol. 2023;102(5):1171\u201384. https:\/\/doi.org\/10.1007\/s00277-023-05148-y.","journal-title":"Ann Hematol"},{"issue":"7","key":"1122_CR91","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.clml.2023.03.007","volume":"23","author":"S Bringhen","year":"2023","unstructured":"Bringhen S, Pour L, Benjamin R, Grosicki S, Min CK, de Farias DLC, et al. Ixazomib versus placebo as postinduction maintenance therapy in newly diagnosed multiple myeloma patients: an analysis by age and frailty status of the TOURMALINE-MM4 study. Clin Lymphoma Myeloma Leuk. 2023;23(7):491\u2013504. https:\/\/doi.org\/10.1016\/j.clml.2023.03.007.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"18","key":"1122_CR92","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1182\/blood.2022019531","volume":"142","author":"L Rosi\u00f1ol","year":"2023","unstructured":"Rosi\u00f1ol L, Oriol A, R\u00edos R, Blanchard MJ, Jarque I, Bargay J, et al. Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma. Blood. 2023;142(18):1518\u201328. https:\/\/doi.org\/10.1182\/blood.2022019531.","journal-title":"Blood"},{"issue":"10","key":"1122_CR93","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1080\/10428194.2023.2255325","volume":"64","author":"M Ng Liet Hing","year":"2023","unstructured":"Ng Liet Hing M, Khot A. Lenalidomide maintenance in myeloma\u2013a goldilocks problem? Leuk Lymphoma. 2023;64(10):1611\u20134. https:\/\/doi.org\/10.1080\/10428194.2023.2255325.","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"1122_CR94","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/S1470-2045(22)00738-0","volume":"24","author":"D Dytfeld","year":"2023","unstructured":"Dytfeld D, Wr\u00f3bel T, Jamroziak K, Kubicki T, Robak P, Walter-Croneck A, et al. Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023;24(2):139\u201350. https:\/\/doi.org\/10.1016\/S1470-2045(22)00738-0.","journal-title":"Lancet Oncol"},{"issue":"29","key":"1122_CR95","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","volume":"35","author":"PL McCarthy","year":"2017","unstructured":"McCarthy PL, Holstein SA, Petrucci MT, Richardson PG, Hulin C, Tosi P, et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol. 2017;35(29):3279\u201389. https:\/\/doi.org\/10.1200\/JCO.2017.72.6679.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1122_CR96","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/ejh.13709","volume":"108","author":"H Gregersen","year":"2022","unstructured":"Gregersen H, Peceliunas V, Remes K, Schjesvold F, Abildgaard N, Nahi H, et al. Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: a randomised phase 2 trial by the Nordic Myeloma Study Group. Eur J Haematol. 2022;108(1):34\u201344. https:\/\/doi.org\/10.1111\/ejh.13709.","journal-title":"Eur J Haematol"},{"issue":"11","key":"1122_CR97","doi-asserted-by":"publisher","first-page":"752.e1","DOI":"10.1016\/j.jtct.2022.07.028","volume":"28","author":"O Pasvolsky","year":"2022","unstructured":"Pasvolsky O, Milton DR, Rauf M, Tanner MR, Bashir Q, Srour S, et al. Lenalidomide-based maintenance after autologous hematopoietic stem cell transplantation for patients with high-risk multiple myeloma. Transplant Cell Ther. 2022;28(11):752.e1-752.e6. https:\/\/doi.org\/10.1016\/j.jtct.2022.07.028.","journal-title":"Transplant Cell Ther."},{"issue":"10192","key":"1122_CR98","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","volume":"394","author":"P Moreau","year":"2019","unstructured":"Moreau P, Attal M, Hulin C, Arnulf B, Belhadj K, Benboubker L, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet. 2019;394(10192):29\u201338. https:\/\/doi.org\/10.1016\/S0140-6736(19)31240-1.","journal-title":"Lancet"},{"issue":"10301","key":"1122_CR99","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","volume":"398","author":"SZ Usmani","year":"2021","unstructured":"Usmani SZ, Garfall AL, Van De Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, et al. Teclistamab, a B-cell maturation antigen \u00d7 CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Lancet. 2021;398(10301):665\u201374. https:\/\/doi.org\/10.1016\/S0140-6736(21)01338-6.","journal-title":"Lancet"},{"issue":"9","key":"1122_CR100","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41591-023-02528-9","volume":"29","author":"AM Lesokhin","year":"2023","unstructured":"Lesokhin AM, Tomasson MH, Arnulf B, Bahlis NJ, Miles Prince H, Niesvizky R, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023;29(9):259\u201367. https:\/\/doi.org\/10.1038\/s41591-023-02528-9.","journal-title":"Nat Med"},{"issue":"2\u20133","key":"1122_CR101","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1007\/s44228-023-00044-8","volume":"5","author":"SM Tariq","year":"2023","unstructured":"Tariq SM, Abdallah AO, Goodman A, Sborov D, Mohyuddin GR, Britt A. The landscape of currently enrolling maintenance trials in multiple myeloma. Clin Hematol Int. 2023;5(2\u20133):170\u20136. https:\/\/doi.org\/10.1007\/s44228-023-00044-8.","journal-title":"Clin Hematol Int."},{"issue":"2","key":"1122_CR102","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.3390\/curroncol30020179","volume":"30","author":"M Widrich","year":"2023","unstructured":"Widrich M. Improving immunotherapeutic treatment strategies for relapsed\/refractory multiple myeloma patients. Curr Oncol. 2023;30(2):2322\u201347. https:\/\/doi.org\/10.3390\/curroncol30020179.","journal-title":"Curr Oncol"},{"issue":"S3","key":"1122_CR103","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1097\/01.HS9.0000967680.90062.ca","volume":"7","author":"NJ Bahlis","year":"2023","unstructured":"Bahlis NJ, Weisel K, Mateos MV, Goldschmidt H, Martin T, Morillo D, et al. S192: Talquetamab (Tal) + daratumumab (dara) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): updated TRIMM-2 results. Hemasphere. 2023;7(S3):210\u20131. https:\/\/doi.org\/10.1097\/01.HS9.0000967680.90062.ca.","journal-title":"Hemasphere."},{"issue":"6","key":"1122_CR104","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1182\/blood-2014-02-556308","volume":"124","author":"N Lendvai","year":"2014","unstructured":"Lendvai N, Hilden P, Devlin S, Landau H, Hassoun H, Lesokhin AM, et al. A phase 2 single-center study of carfilzomib 56 mg\/m2 with or without low-dose dexamethasone in relapsed multiple myeloma. Blood. 2014;124(6):899\u2013906. https:\/\/doi.org\/10.1182\/blood-2014-02-556308.","journal-title":"Blood"},{"issue":"S3","key":"1122_CR105","doi-asserted-by":"publisher","first-page":"4057","DOI":"10.1097\/01.HS9.0000975232.20009.f4","volume":"7","author":"M Hultcrantz","year":"2023","unstructured":"Hultcrantz M, Kleinman D, Vij R, Escalante F, Delforge M, Kotowsky N, et al. PB2114: Belantamab mafodotin for relapsed\/refractory multiple myeloma: a real-world observational study update. Hemasphere. 2023;7(S3):4057\u20138. https:\/\/doi.org\/10.1097\/01.HS9.0000975232.20009.f4.","journal-title":"Hemasphere."},{"issue":"11","key":"1122_CR106","doi-asserted-by":"publisher","first-page":"775","DOI":"10.2217\/fon-2022-1018","volume":"19","author":"P Hlavacek","year":"2023","unstructured":"Hlavacek P, Schepart A, Silverstein AR, Petrilla AA, Johnson W, Schroeder A. Medicare characteristics, treatment, cost and survival in triple class exposed relapsed or refractory multiple myeloma. Future Oncol. 2023;19(11):775\u201387. https:\/\/doi.org\/10.2217\/fon-2022-1018.","journal-title":"Future Oncol"},{"issue":"181","key":"1122_CR107","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-023-00946-z","volume":"13","author":"A Visram","year":"2023","unstructured":"Visram A, De La Torre A, White D, Su J, Masih-Khan E, Chu M, et al. Real-world data on outcomes of anti-CD38 antibody treated, including triple class refractory, patients with multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database. Blood Cancer J. 2023;13(181):1\u20137. https:\/\/doi.org\/10.1038\/s41408-023-00946-z.","journal-title":"Blood Cancer J"},{"issue":"7","key":"1122_CR108","doi-asserted-by":"publisher","first-page":"A715","DOI":"10.1016\/j.jval.2016.09.2114","volume":"19","author":"X Gatopoulou","year":"2016","unstructured":"Gatopoulou X, Bardenheuer K, Van Hoorenbeeck S, Kempel A. PCN42\u2014treatment patterns of relapsed and refractory multiple myeloma in Europe (EU-28). Value Health. 2016;19(7):A715\u20136. https:\/\/doi.org\/10.1016\/j.jval.2016.09.2114.","journal-title":"Value Health."},{"issue":"7","key":"1122_CR109","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.3390\/cancers12071759","volume":"12","author":"C Wang","year":"2020","unstructured":"Wang C, Soekojo CY, Mel S, Ooi M, Chen Y, Goh AZK, et al. Natural history and prognostic factors at first relapse in multiple myeloma. Cancers (Basel). 2020;12(7):1759. https:\/\/doi.org\/10.3390\/cancers12071759.","journal-title":"Cancers (Basel)."},{"issue":"8","key":"1122_CR110","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/AJH.26590","volume":"97","author":"SV Rajkumar","year":"2022","unstructured":"Rajkumar SV. Multiple Myeloma: 2022 update on diagnosis, risk-stratification and management. Am J Hematol. 2022;97(8):1086\u2013107. https:\/\/doi.org\/10.1002\/AJH.26590.","journal-title":"Am J Hematol"},{"issue":"1","key":"1122_CR111","doi-asserted-by":"publisher","first-page":"53","DOI":"10.17925\/OHR.2022.18.1.53","volume":"18","author":"S Vasudevan","year":"2022","unstructured":"Vasudevan S, Gundarlapalli S, Thalambedu N, Mohan M. Updates in the management of multiple myeloma from the American Society of Hematology meeting 2021. Oncol Haematol. 2022;18(1):53. https:\/\/doi.org\/10.17925\/OHR.2022.18.1.53.","journal-title":"Oncol Haematol."},{"issue":"1","key":"1122_CR112","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/S40164-023-00402-5","volume":"12","author":"W Li","year":"2023","unstructured":"Li W, Zhang B, Cao W, Zhang W, Li T, Liu L, et al. Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed\/refractory multiple myeloma through single-cell sequencing. Exp Hematol Oncol. 2023;12(1):44. https:\/\/doi.org\/10.1186\/S40164-023-00402-5.","journal-title":"Exp Hematol Oncol"},{"issue":"6","key":"1122_CR113","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.3390\/cancers15061682","volume":"15","author":"P Weir","year":"2023","unstructured":"Weir P, Donaldson D, McMullin MF, Crawford L. Metabolic alterations in multiple myeloma: from oncogenesis to proteasome inhibitor resistance. Cancers (Basel). 2023;15(6):1682. https:\/\/doi.org\/10.3390\/cancers15061682.","journal-title":"Cancers (Basel)."},{"issue":"1","key":"1122_CR114","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.currproblcancer.2009.01.001","volume":"33","author":"SV Rajkumar","year":"2009","unstructured":"Rajkumar SV. Multiple myeloma. Curr Probl Cancer. 2009;33(1):7\u201364. https:\/\/doi.org\/10.1016\/j.currproblcancer.2009.01.001.","journal-title":"Curr Probl Cancer"},{"key":"1122_CR115","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1146\/annurev-med-070209-175325","volume":"62","author":"J Laubach","year":"2011","unstructured":"Laubach J, Richardson P, Anderson K. Multiple myeloma. Annu Rev Med. 2011;62:249\u201364. https:\/\/doi.org\/10.1146\/annurev-med-070209-175325.","journal-title":"Annu Rev Med"},{"issue":"S2","key":"1122_CR116","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1097\/01.HS9.0000936080.11311.30","volume":"7","author":"M Gavriatopoulou","year":"2023","unstructured":"Gavriatopoulou M. Treatment of triple-class refractory disease: beyond immunotherapy. HemaSphere. 2023;7(S2):2\u20133. https:\/\/doi.org\/10.1097\/01.HS9.0000936080.11311.30.","journal-title":"HemaSphere."},{"issue":"9","key":"1122_CR117","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1007\/s00277-023-05212-7","volume":"102","author":"AK Stewart","year":"2023","unstructured":"Stewart AK, Rajkumar VS, Dimopoulos MA, Masszi T, \u0160pi\u010dka I, Oriol A, et al. Efficacy and safety of ixazomib plus lenalidomide and dexamethasone following injectable pi-based therapy in relapsed\/refractory multiple myeloma. Ann Hematol. 2023;102(9):2493\u2013504. https:\/\/doi.org\/10.1007\/s00277-023-05212-7.","journal-title":"Ann Hematol"},{"issue":"11","key":"1122_CR118","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1002\/cam4.4313","volume":"11","author":"M Shen","year":"2022","unstructured":"Shen M, Zhang J, Tang R, Wang Y, Zhan X, Fan S, et al. Ixazomib-based maintenance therapy after bortezomib-based induction in patients with multiple myeloma not undergoing transplantation: a real-world study. Cancer Med. 2022;11(11):2173\u201383. https:\/\/doi.org\/10.1002\/cam4.4313.","journal-title":"Cancer Med"},{"issue":"5","key":"1122_CR119","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s40265-017-0689-1","volume":"77","author":"SA Holstein","year":"2017","unstructured":"Holstein SA, McCarthy PL. Immunomodulatory drugs in multiple myeloma: mechanisms of action and clinical experience. Drugs. 2017;77(5):505\u201320. https:\/\/doi.org\/10.1007\/s40265-017-0689-1.","journal-title":"Drugs"},{"issue":"1","key":"1122_CR120","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41408-024-00988-x","volume":"14","author":"IV Kostopoulos","year":"2024","unstructured":"Kostopoulos IV, Fotiou D, Gavriatopoulou M, Rousakis P, Ntanasis-Stathopoulos I, Panteli C, et al. Efficacy and immune modulation associated with the addition of IMiDs to daratumumab backbone in multiple myeloma patients refractory to both drug classes: resetting synergistic activity. Blood Cancer J. 2024;14(1):26. https:\/\/doi.org\/10.1038\/s41408-024-00988-x.","journal-title":"Blood Cancer J"},{"issue":"3","key":"1122_CR121","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s00277-021-04404-3","volume":"100","author":"LJ Arcuri","year":"2021","unstructured":"Arcuri LJ, Americo AD. Treatment of relapsed\/refractory multiple myeloma in the bortezomib and lenalidomide era: a systematic review and network meta-analysis. Ann Hematol. 2021;100(3):725\u201334. https:\/\/doi.org\/10.1007\/s00277-021-04404-3.","journal-title":"Ann Hematol"},{"issue":"3","key":"1122_CR122","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/bjh.12129","volume":"160","author":"JR Berenson","year":"2013","unstructured":"Berenson JR, Yellin O, Bessudo A, Boccia RV, Noga SJ, Gravenor DS. Phase I\/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. Br J Haematol. 2013;160(3):321\u201330. https:\/\/doi.org\/10.1111\/bjh.12129.","journal-title":"Br J Haematol"},{"issue":"7","key":"1122_CR123","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1182\/blood-2013-08-521468","volume":"123","author":"H Ludwig","year":"2014","unstructured":"Ludwig H, Kasparu H, Leitgeb C, Rauch E, Linkesch W, Zojer N, et al. Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma. Blood. 2014;123(7):985\u201391. https:\/\/doi.org\/10.1182\/blood-2013-08-521468.","journal-title":"Blood"},{"issue":"20","key":"1122_CR124","doi-asserted-by":"publisher","first-page":"4608","DOI":"10.1182\/blood-2011-12-395715","volume":"119","author":"S Lentzsch","year":"2012","unstructured":"Lentzsch S, O\u2019Sullivan A, Kennedy R, Abbas M, Dai L, Pregja L, et al. Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1\/2 open-label, dose escalation study. Blood. 2012;119(20):4608\u201313. https:\/\/doi.org\/10.1182\/blood-2011-12-395715.","journal-title":"Blood"},{"issue":"Spec Feature","key":"1122_CR125","first-page":"111","volume":"9","author":"LA Raedler","year":"2016","unstructured":"Raedler LA. Pomalyst (pomalidomide) received a new indication for patients with relapsed and\/or refractory multiple myeloma. Am Health Drug Benef. 2016;9(Spec Feature):111\u20134.","journal-title":"Am Health Drug Benef"},{"issue":"11","key":"1122_CR126","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","volume":"14","author":"JS Miguel","year":"2013","unstructured":"Miguel JS, Weisel K, Moreau P, Lacy M, Song K, Delforge M, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14(11):1055\u201366. https:\/\/doi.org\/10.1016\/S1470-2045(13)70380-2.","journal-title":"Lancet Oncol"},{"key":"1122_CR127","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.exphem.2022.07.303","volume":"114","author":"J Afari","year":"2022","unstructured":"Afari J, Spektor TM, Turner C, Cohen A, Bessudo A, Jhangiani H, et al. Efficacy and safety of replacing lenalidomide with pomalidomide for patients with multiple myeloma refractory to a lenalidomide-containing combination regimen. Exp Hematol. 2022;114:54\u201360. https:\/\/doi.org\/10.1016\/j.exphem.2022.07.303.","journal-title":"Exp Hematol"},{"issue":"1","key":"1122_CR128","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/leu.2009.236","volume":"24","author":"H Quach","year":"2010","unstructured":"Quach H, Ritchie D, Stewart AK, Neeson P, Harrison S, Smyth MJ, et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia. 2010;24(1):22\u201332. https:\/\/doi.org\/10.1038\/leu.2009.236.","journal-title":"Leukemia"},{"issue":"9","key":"1122_CR129","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2013.38","volume":"3","author":"AA Chanan-Khan","year":"2013","unstructured":"Chanan-Khan AA, Swaika A, Paulus A, Kumar SK, Mikhael JR, Rajkumar SV, et al. Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma. Blood Cancer J. 2013;3(9): e143. https:\/\/doi.org\/10.1038\/bcj.2013.38.","journal-title":"Blood Cancer J"},{"issue":"10","key":"1122_CR130","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/HS9.0000000000000786","volume":"6","author":"P Sonneveld","year":"2022","unstructured":"Sonneveld P, Zweegman S, Cavo M, Nasserinejad K, Broijl A, Troia R, et al. Carfilzomib, pomalidomide, and dexamethasone as second-line therapy for lenalidomide-refractory multiple myeloma. Hemasphere. 2022;6(10):1\u20138. https:\/\/doi.org\/10.1097\/HS9.0000000000000786.","journal-title":"Hemasphere."},{"issue":"1","key":"1122_CR131","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40364-021-00344-2","volume":"10","author":"J\u00c1 Hern\u00e1ndez-Rivas","year":"2022","unstructured":"Hern\u00e1ndez-Rivas J\u00c1, R\u00edos-Tamayo R, Encinas C, Alonso R, Lahuerta JJ. The changing landscape of relapsed and\/or refractory multiple myeloma (MM): fundamentals and controversies. Biomark Res. 2022;10(1):1. https:\/\/doi.org\/10.1186\/s40364-021-00344-2.","journal-title":"Biomark Res."},{"issue":"21","key":"1122_CR132","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1182\/blood-2015-11-682518","volume":"127","author":"RC Baz","year":"2016","unstructured":"Baz RC, Martin TG 3rd, Lin HY, Zhao X, Shain KH, Cho HJ, et al. Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma. Blood. 2016;127(21):2561\u20138. https:\/\/doi.org\/10.1182\/blood-2015-11-682518.","journal-title":"Blood"},{"issue":"9","key":"1122_CR133","doi-asserted-by":"publisher","first-page":"6569","DOI":"10.1007\/s00432-023-04637-x","volume":"149","author":"A Brioli","year":"2023","unstructured":"Brioli A, Gengenbach L, Mancuso K, Binder M, Ernst T, Heidel FH, et al. Pomalidomide combinations are a safe and effective option after daratumumab failure. J Cancer Res Clin Oncol. 2023;149(9):6569\u201374. https:\/\/doi.org\/10.1007\/s00432-023-04637-x.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"1122_CR134","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","volume":"17","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, H\u00e1jek R, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17(1):27\u201338. https:\/\/doi.org\/10.1016\/S1470-2045(15)00464-7.","journal-title":"Lancet Oncol"},{"issue":"7","key":"1122_CR135","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1038\/leu.2014.27","volume":"28","author":"JR Berenson","year":"2014","unstructured":"Berenson JR, Hilger JD, Yellin O, Dichmann R, Patel-Donnelly D, Boccia RV, et al. Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy. Leukemia. 2014;28(7):1529\u201336. https:\/\/doi.org\/10.1038\/leu.2014.27.","journal-title":"Leukemia"},{"issue":"5","key":"1122_CR136","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1111\/EJH.14082","volume":"111","author":"R LeBlanc","year":"2023","unstructured":"LeBlanc R, Mian H, Reece D, Su J, Masih-Khan E, Chu M, Jimenez-Zepeda V, et al. Outcome of carfilzomib\/pomalidomide-based regimens after daratumumab-based treatment in relapsed multiple myeloma: a Canadian Myeloma Research Group database analysis. Eur J Haematol. 2023;111(5):815\u201323. https:\/\/doi.org\/10.1111\/EJH.14082.","journal-title":"Eur J Haematol"},{"issue":"7","key":"1122_CR137","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1505654","volume":"373","author":"S Lonial","year":"2015","unstructured":"Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373(7):621\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1505654.","journal-title":"N Engl J Med"},{"issue":"9","key":"1122_CR138","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41408-020-00357-4","volume":"10","author":"MA Dimopoulos","year":"2020","unstructured":"Dimopoulos MA, Lonial S, White D, Moreau P, Weisel K, San-Miguel J, et al. Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study. Blood Cancer J. 2020;10(9):91. https:\/\/doi.org\/10.1038\/s41408-020-00357-4.","journal-title":"Blood Cancer J"},{"issue":"3","key":"1122_CR139","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1200\/JCO.21.02815","volume":"41","author":"MA Dimopoulos","year":"2022","unstructured":"Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M, et al. Elotuzumab plus pomalidomide and dexamethasone for relapsed\/refractory multiple myeloma: final overall survival analysis from the randomized phase II ELOQUENT-3 trial. J Clin Oncol. 2022;41(3):568\u201378. https:\/\/doi.org\/10.1200\/JCO.21.02815.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1122_CR140","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1177\/2040620716657993","volume":"7","author":"H Einsele","year":"2016","unstructured":"Einsele H, Schreder M. Treatment of multiple myeloma with the immunostimulatory SLAMF7 antibody elotuzumab. Ther Adv Hematol. 2016;7(5):288\u2013301. https:\/\/doi.org\/10.1177\/2040620716657993.","journal-title":"Ther Adv Hematol."},{"issue":"1","key":"1122_CR141","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3324\/haematol.2021.279930","volume":"108","author":"K Richardson","year":"2023","unstructured":"Richardson K, Keam SP, Zhu JJ, Meyran D, D\u2019Souza C, Macdonald S, et al. The efficacy of combination treatment with elotuzumab and lenalidomide is dependent on crosstalk between natural killer cells, monocytes and myeloma cells. Haematologica. 2023;108(1):83\u201397. https:\/\/doi.org\/10.3324\/haematol.2021.279930.","journal-title":"Haematologica"},{"issue":"11","key":"1122_CR142","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.clml.2020.06.001","volume":"20","author":"S Meyers","year":"2020","unstructured":"Meyers S, Henning C, Swift R, Eades B, Spektor TM, Berenson JR. Treatment with elotuzumab in combination with dexamethasone achieves a complete remission in a previously treated patient with multiple myeloma: a case report. Clin Lymphoma Myeloma Leuk. 2020;20(11):801\u20134. https:\/\/doi.org\/10.1016\/j.clml.2020.06.001.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"1122_CR143","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12010015","volume":"12","author":"F Bonello","year":"2019","unstructured":"Bonello F, Mina R, Boccadoro M, Gay F. Therapeutic monoclonal antibodies and antibody products: current practices and development in multiple myeloma. Cancers (Basel). 2019;12(1):1\u201324. https:\/\/doi.org\/10.3390\/cancers12010015.","journal-title":"Cancers (Basel)."},{"issue":"12","key":"1122_CR144","doi-asserted-by":"publisher","first-page":"3526","DOI":"10.1038\/s41375-021-01262-w","volume":"35","author":"SZ Usmani","year":"2021","unstructured":"Usmani SZ, Karanes C, Bensinger WI, D\u2019Souza A, Raje N, Tuchman SA, et al. Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed\/refractory multiple myeloma. Leukemia. 2021;35(12):3526\u201333. https:\/\/doi.org\/10.1038\/s41375-021-01262-w.","journal-title":"Leukemia"},{"issue":"S2","key":"1122_CR145","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1097\/01.HS9.0000936332.73280.E0","volume":"7","author":"M Hanna","year":"2023","unstructured":"Hanna M, Chorazy J, Iheanacho I, Gorsh B, Wang PF, Paka P, et al. P51efficacy and safety of third-line or later treatments, including the cd38 monoclonal antibody class, in patients with relapsed\/refractory multiple myeloma: a systematic literature review. HemaSphere. 2023;7(S2):38\u20139. https:\/\/doi.org\/10.1097\/01.HS9.0000936332.73280.E0.","journal-title":"HemaSphere."},{"key":"1122_CR146","doi-asserted-by":"publisher","first-page":"7891","DOI":"10.2147\/CMAR.S212526","volume":"12","author":"D Dima","year":"2020","unstructured":"Dima D, Dower J, Comenzo RL, Varga C. Evaluating daratumumab in the treatment of multiple myeloma: safety, efficacy and place in therapy. Cancer Manag Res. 2020;12:7891\u2013903. https:\/\/doi.org\/10.2147\/CMAR.S212526.","journal-title":"Cancer Manag Res."},{"issue":"4","key":"1122_CR147","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1111\/ejh.14057","volume":"111","author":"BS Regidor","year":"2023","unstructured":"Regidor BS, Jew S, Goldwater MS, Beatty BM, Bujarski S, ElSayed A, et al. Efficacy of isatuximab in combination with steroids for the treatment of relapsed\/refractory multiple myeloma patients exhibiting only biochemical progression\u2014a single center retrospective study. Eur J Haematol. 2023;111(4):628\u201335. https:\/\/doi.org\/10.1111\/ejh.14057.","journal-title":"Eur J Haematol"},{"issue":"104041","key":"1122_CR148","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.critrevonc.2023.104041","volume":"188","author":"P Neri","year":"2023","unstructured":"Neri P, Nijhof I. Evidence-based mechanisms of synergy with IMiD agent-based combinations in multiple myeloma. Crit Rev Oncol Hematol. 2023;188(104041):1\u201314. https:\/\/doi.org\/10.1016\/j.critrevonc.2023.104041.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1017990","key":"1122_CR149","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2022.1017990","volume":"13","author":"H Guo","year":"2022","unstructured":"Guo H, Yang J, Wang H, Liu X, Liu Y, Zhou K. Reshaping the tumor microenvironment: the versatility of immunomodulatory drugs in B-cell neoplasms. Front Immunol. 2022;13(1017990):1\u201318. https:\/\/doi.org\/10.3389\/fimmu.2022.1017990.","journal-title":"Front Immunol"},{"issue":"1352281","key":"1122_CR150","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fonc.2024.1352281","volume":"14","author":"D White","year":"2024","unstructured":"White D, Schiller GJ, Madan S, Lentzsch S, Chubar E, Lavi N, et al. Efficacy and safety of 40 mg vs 60 mg once weekly selinexor in combination with pomalidomide and dexamethasone in relapsed and\/or refractory multiple myeloma (RRMM). Front Oncol. 2024;14(1352281):1\u20139. https:\/\/doi.org\/10.3389\/fonc.2024.1352281.","journal-title":"Front Oncol"},{"issue":"S1","key":"1122_CR151","doi-asserted-by":"publisher","first-page":"43","DOI":"10.5045\/BR.2020.S008","volume":"55","author":"JH Lee","year":"2020","unstructured":"Lee JH, Kim SH. Treatment of relapsed and refractory multiple myeloma. Blood Res. 2020;55(S1):43\u201353. https:\/\/doi.org\/10.5045\/BR.2020.S008.","journal-title":"Blood Res."},{"issue":"16","key":"1122_CR152","doi-asserted-by":"publisher","first-page":"8008","DOI":"10.1200\/JCO.2023.41.16_suppl.8008","volume":"41","author":"AK Nooka","year":"2023","unstructured":"Nooka AK, Lesokhin AM, Mohty M, Niesvizky R, Maisel C, Arnulf B, et al. Efficacy and safety of elranatamab in patients with relapsed\/refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: a pooled analysis from MagnetisMM studies. J Clin Oncol. 2023;41(16):8008. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.8008.","journal-title":"J Clin Oncol"},{"issue":"15","key":"1122_CR153","doi-asserted-by":"publisher","first-page":"8013","DOI":"10.1200\/JCO.2017.35.15_suppl.8013","volume":"35","author":"JR Berenson","year":"2017","unstructured":"Berenson JR, Cohen A, Spektor TM, Bitran JD, Chem GQ, Moezi MM, et al. Replacement of ixazomib for relapsed\/refractory multiple myeloma patients refractory to a bortezomib or carfilzomib-containing combination therapy. J Clin Oncol. 2017;35(15):8013. https:\/\/doi.org\/10.1200\/JCO.2017.35.15_suppl.8013.","journal-title":"J Clin Oncol"},{"issue":"16","key":"1122_CR154","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.e2004","volume":"41","author":"N Biran","year":"2023","unstructured":"Biran N, Vesole DH, Parmar HV, Phull P, Doucette K, Feinman R, et al. A phase IIb study of selinexor in combination with carfilzomib, daratumumab, or pomalidomide in patients with multiple myeloma relapsing on current therapy. J Clin Oncol. 2023;41(16): e20042. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.e2004.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1122_CR155","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1002\/jha2.709","volume":"4","author":"CC Mo","year":"2023","unstructured":"Mo CC, Yee AJ, Midha S, Hartley-Brown MA, Nadeem O, O\u2019Donnell EK, et al. Selinexor: targeting a novel pathway in multiple myeloma. eJHaem. 2023;4(3):792\u2013810. https:\/\/doi.org\/10.1002\/jha2.709.","journal-title":"eJHaem."},{"key":"1122_CR156","doi-asserted-by":"publisher","first-page":"65","DOI":"10.18632\/oncotarget.28547","volume":"15","author":"A Del Dosso","year":"2024","unstructured":"Del Dosso A, Tadevosyan E, Berenson JR. Preclinical and clinical evaluation of the Janus Kinase inhibitor ruxolitinib in multiple myeloma. Oncotarget. 2024;15:65\u201375. https:\/\/doi.org\/10.18632\/oncotarget.28547.","journal-title":"Oncotarget"},{"issue":"26","key":"1122_CR157","doi-asserted-by":"publisher","first-page":"3604","DOI":"10.1182\/blood.2020007899","volume":"137","author":"VA Gupta","year":"2021","unstructured":"Gupta VA, Barwick BG, Matulis SM, Shirasaki R, Jaye DL, Keats JJ, et al. Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression. Blood. 2021;137(26):3604\u201315. https:\/\/doi.org\/10.1182\/blood.2020007899.","journal-title":"Blood"},{"issue":"1291920","key":"1122_CR158","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2023.1291920","volume":"14","author":"Q Cao","year":"2023","unstructured":"Cao Q, Wu X, Zhang Q, Gong J, Chen Y, You Y, et al. Mechanisms of action of the BCL-2 inhibitor venetoclax in multiple myeloma: a literature review. Front Pharmacol. 2023;14(1291920):1\u20137. https:\/\/doi.org\/10.3389\/fphar.2023.1291920.","journal-title":"Front Pharmacol"},{"issue":"1","key":"1122_CR159","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1080\/07853890.2023.2186480","volume":"55","author":"W He","year":"2023","unstructured":"He W, He F, Hu H. Efficacy and safety of Venetoclax-based regimens in relapsed or refractory multiple myeloma: a systematic review and meta-analysis of prospective clinical trials. Ann Med. 2023;55(1):1029\u201336. https:\/\/doi.org\/10.1080\/07853890.2023.2186480.","journal-title":"Ann Med"},{"issue":"3","key":"1122_CR160","doi-asserted-by":"publisher","first-page":"979","DOI":"10.3324\/haematol.2023.283472","volume":"109","author":"MJ Steinhardt","year":"2024","unstructured":"Steinhardt MJ, Truger M, Bittrich M, Zhou X, Noderer J, Riedhammer C, et al. Venetoclax salvage therapy in relapsed\/refractory multiple myeloma. Haematologica. 2024;109(3):979\u201381. https:\/\/doi.org\/10.3324\/haematol.2023.283472.","journal-title":"Haematologica"},{"issue":"32","key":"1122_CR161","doi-asserted-by":"publisher","first-page":"3602","DOI":"10.1200\/JCO.21.00443","volume":"39","author":"NJ Bahlis","year":"2021","unstructured":"Bahlis NJ, Baz R, Harrison SJ, Quach H, Ho SJ, Vangsted AJ, et al. Phase I study of venetoclax plus daratumumab and dexamethasone, with or without bortezomib, in patients with relapsed or refractory multiple myeloma with and without t(11;14). J Clin Oncol. 2021;39(32):3602\u201312. https:\/\/doi.org\/10.1200\/JCO.21.00443.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1122_CR162","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/ejh.13896","volume":"110","author":"BS Regidor","year":"2023","unstructured":"Regidor BS, Siddiqi D, Beatty BM, Goldwater MS, Jew S, Bujarski S, et al. Efficacy of venetoclax plus anti-CD38 monoclonal antibody-containing therapies among t(11;14) positive multiple myeloma patients regardless of timing of prior treatment with this antibody. Eur J Haematol. 2023;110(2):222\u20133. https:\/\/doi.org\/10.1111\/ejh.13896.","journal-title":"Eur J Haematol"},{"issue":"8","key":"1122_CR163","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1007\/s00277-021-04555-3","volume":"100","author":"B Regidor","year":"2021","unstructured":"Regidor B, Goldwater MS, Wang J, Bujarski S, Swift R, Eades B, et al. Low dose venetoclax in combination with bortezomib, daratumumab, and dexamethasone for the treatment of relapsed\/refractory multiple myeloma patients\u2014a single-center retrospective study. Ann Hematol. 2021;100(8):2061\u201370. https:\/\/doi.org\/10.1007\/s00277-021-04555-3.","journal-title":"Ann Hematol"},{"issue":"23","key":"1122_CR164","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1556\/650.2023.32790","volume":"164","author":"VR Szita","year":"2023","unstructured":"Szita VR, Wiedemann \u00c1, Syoreni S, T\u00f3th A, Ruff E, Ga\u00e1l L, et al. Venetoclax-based salvage in multiple myeloma with (11;14) translocation after suboptimal response to first-line therapy. Orv Hetil. 2023;164(23):894\u20139. https:\/\/doi.org\/10.1556\/650.2023.32790.","journal-title":"Orv Hetil"},{"key":"1122_CR165","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2040620720930629","volume":"11","author":"J Richter","year":"2020","unstructured":"Richter J, Madduri D, Richard S, Chari A. Selinexor in relapsed\/refractory multiple myeloma. Ther Adv Hematol. 2020;11:1\u201310. https:\/\/doi.org\/10.1177\/2040620720930629.","journal-title":"Ther Adv Hematol."},{"issue":"8","key":"1122_CR166","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa1903455","volume":"381","author":"A Chari","year":"2019","unstructured":"Chari A, Vogl DT, Gavriatopoulou M, Nooka AK, Yee AJ, Huff CA, et al. Oral selinexor\u2013dexamethasone for triple-class refractory multiple myeloma. N Engl J Med. 2019;381(8):727\u201338. https:\/\/doi.org\/10.1056\/NEJMoa1903455.","journal-title":"N Engl J Med"},{"issue":"10262","key":"1122_CR167","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/S0140-6736(20)32292-3","volume":"396","author":"S Grosicki","year":"2020","unstructured":"Grosicki S, Simonova M, Spicka I, Pour L, Kriachok I, Gavriatopoulou M, et al. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. Lancet. 2020;396(10262):1563\u201373. https:\/\/doi.org\/10.1016\/S0140-6736(20)32292-3.","journal-title":"Lancet"},{"key":"1122_CR168","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/20406207231219442","volume":"15","author":"Q Huang","year":"2024","unstructured":"Huang Q, Zhao R, Xu L, Hao X, Tao S. Treatment of multiple myeloma with selinexor: a review. Ther Adv Hematol. 2024;15:1\u201317. https:\/\/doi.org\/10.1177\/20406207231219442.","journal-title":"Ther Adv Hematol."},{"issue":"9","key":"1122_CR169","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.clml.2023.06.001","volume":"23","author":"GJ Schiller","year":"2023","unstructured":"Schiller GJ, Lipe BC, Bahlis NJ, Tuchman SA, Bensinger WI, Sutherland HJ, et al. Selinexor-based triplet regimens in patients with multiple myeloma previously treated with anti-cd38 monoclonal antibodies. Clin Lymphoma Myeloma Leuk. 2023;23(9):286\u201396. https:\/\/doi.org\/10.1016\/j.clml.2023.06.001.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1122_CR170","doi-asserted-by":"publisher","DOI":"10.58931\/cht.2023.2s0736","author":"M Louzada","year":"2023","unstructured":"Louzada M, McCurdy A, Pavic M, Venner C. Navigating challenging treatment decisions in relapsed and refractory multiple myeloma (RRMM). Can Hematol Today. 2023. https:\/\/doi.org\/10.58931\/cht.2023.2s0736.","journal-title":"Can Hematol Today."},{"issue":"6","key":"1122_CR171","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1111\/bjh.18593","volume":"200","author":"JR Berenson","year":"2023","unstructured":"Berenson JR, Martinez D, Safaie T, Boccia R, Yang H, Moezi M, et al. Ruxolitinib and methylprednisolone for treatment of patients with relapsed\/refractory multiple myeloma. Br J Haematol. 2023;200(6):722\u201330. https:\/\/doi.org\/10.1111\/bjh.18593.","journal-title":"Br J Haematol"},{"issue":"10","key":"1122_CR172","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1158\/1078-0432.CCR-19-1899","volume":"26","author":"JR Berenson","year":"2020","unstructured":"Berenson JR, To J, Spektor TM, Martinez D, Turner C, Sanchez A, et al. A phase I study of ruxolitinib, lenalidomide, and steroids for patients with relapsed\/refractory multiple myeloma. Clin Cancer Res. 2020;26(10):2346\u201353. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1899.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1122_CR173","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s11523-024-01049-w","volume":"19","author":"JR Berenson","year":"2024","unstructured":"Berenson JR, Limon A, Rice S, Safaie T, Boccia R, Yang H, et al. A phase I trial evaluating the addition of lenalidomide to patients with relapsed\/refractory multiple myeloma progressing on ruxolitinib and methylprednisolone. Target Oncol. 2024;19(3):343\u201357. https:\/\/doi.org\/10.1007\/s11523-024-01049-w.","journal-title":"Target Oncol"},{"issue":"9","key":"1122_CR174","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1158\/1078-0432.CCR-21-3803","volume":"28","author":"P Sharma","year":"2022","unstructured":"Sharma P, Kanapuru B, George B, Lin X, Xu Z, Bryan WW, et al. FDA approval summary: idecabtagene vicleucel for relapsed or refractory multiple myeloma. Clin Cancer Res. 2022;28(9):1759\u201364. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-3803.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"1122_CR175","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1200\/JCO.22.01365","volume":"41","author":"DK Hansen","year":"2023","unstructured":"Hansen DK, Sidana S, Peres LC, Colin Leitzinger C, Shune L, Shrewsbury A, et al. Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the myeloma Car T consortium. J Clin Oncol. 2023;41(11):2087\u201397. https:\/\/doi.org\/10.1200\/JCO.22.01365.","journal-title":"J Clin Oncol"},{"key":"1122_CR176","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.991092","author":"E Chekol Abebe","year":"2022","unstructured":"Chekol Abebe E, Yibeltal Shiferaw M, Tadele Admasu F, Asmamaw Dejenie T. Ciltacabtagene autoleucel: the second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma. Front Immunol. 2022. https:\/\/doi.org\/10.3389\/fimmu.2022.991092.","journal-title":"Front Immunol"},{"issue":"6","key":"1122_CR177","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1200\/JCO.22.00842","volume":"41","author":"T Martin","year":"2023","unstructured":"Martin T, Usmani SZ, Berdeja JG, Agha M, Cohen AD, Hari P, et al. Ciltacabtagene autoleucel, an anti-b-cell maturation antigen chimeric antigen receptor t-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol. 2023;41(6):1265\u201374. https:\/\/doi.org\/10.1200\/JCO.22.00842.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1122_CR178","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1200\/OP.22.00819","volume":"19","author":"P Strati","year":"2023","unstructured":"Strati P, Gregory T, Majhail NS, Jain N. Chimeric antigen receptor T-cell therapy for hematologic malignancies: a practical review. JCO Oncol Pract. 2023;19(9):706\u201313. https:\/\/doi.org\/10.1200\/OP.22.00819.","journal-title":"JCO Oncol Pract."},{"key":"1122_CR179","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_389860","volume":"43","author":"H Hosoya","year":"2023","unstructured":"Hosoya H, Rodriguez-Otero P, Sidana S, Borrello IM. Embracing myeloma chimeric antigen receptor-t: from scientific design to clinical impact. Am Soc Clin Oncol Educ Book. 2023;43: e389860. https:\/\/doi.org\/10.1200\/EDBK_389860.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"1122_CR180","doi-asserted-by":"publisher","first-page":"1206475","DOI":"10.3389\/fonc.2023.1206475","volume":"13","author":"J Richter","year":"2023","unstructured":"Richter J, Anderson LD, Ramasamy K, Rossi A. Editorial. T-cell directed therapies in multiple myeloma. Front Oncol. 2023;13:1206475. https:\/\/doi.org\/10.3389\/fonc.2023.1206475.","journal-title":"Front Oncol"},{"issue":"6","key":"1122_CR181","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol. 2023;20(6):359\u201371. https:\/\/doi.org\/10.1038\/s41571-023-00754-1.","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"1122_CR182","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1007\/s12325-023-02551-9","volume":"40","author":"O Landgren","year":"2023","unstructured":"Landgren O, Nadeem O. Bispecific monoclonal antibodies in multiple myeloma: data from ASH 2022: a podcast. Adv Ther. 2023;40(8):3291\u2013303. https:\/\/doi.org\/10.1007\/s12325-023-02551-9.","journal-title":"Adv Ther"},{"issue":"16","key":"1122_CR183","doi-asserted-by":"publisher","first-page":"8036","DOI":"10.1200\/JCO.2023.41.16_suppl.8036","volume":"41","author":"CD Schinke","year":"2023","unstructured":"Schinke CD, Touzeau C, Minnema MC, van de Donk NWCJ, Rodr\u00edguez-Otero P, Mateos MV, et al. Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed\/refractory multiple myeloma (RRMM). J Clin Oncol. 2023;41(16):8036\u2013136. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.8036.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1122_CR184","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387(6):495\u2013505. https:\/\/doi.org\/10.1056\/NEJMoa2203478.","journal-title":"N Engl J Med"},{"issue":"16","key":"1122_CR185","doi-asserted-by":"publisher","first-page":"8002","DOI":"10.1200\/JCO.2023.41.16_suppl.8002","volume":"41","author":"YC Cohen","year":"2023","unstructured":"Cohen YC, Morillo D, Gatt ME, Sebag M, Kim K, Min CK, et al. First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed\/refractory multiple myeloma (RRMM). J Clin Oncol. 2023;41(16):8002. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.8002.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1122_CR186","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","volume":"29","author":"H Lee","year":"2023","unstructured":"Lee H, Ahn S, Maity R, Leblay N, Ziccheddu B, Truger M, et al. Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma. Nat Med. 2023;29(9):2295\u2013306. https:\/\/doi.org\/10.1038\/s41591-023-02491-5.","journal-title":"Nat Med"},{"issue":"2","key":"1122_CR187","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3390\/antib12020038","volume":"12","author":"R Khanam","year":"2023","unstructured":"Khanam R, Ashruf OS, Bin Waqar SH, Shah Z, Batool S, Mehreen R, et al. The role of bispecific antibodies in relapsed refractory multiple myeloma: a systematic review. Antibodies (Basel). 2023;12(2):38. https:\/\/doi.org\/10.3390\/antib12020038.","journal-title":"Antibodies (Basel)."},{"issue":"17","key":"1122_CR188","doi-asserted-by":"publisher","first-page":"5539","DOI":"10.3390\/jcm12175539","volume":"12","author":"R Khanam","year":"2023","unstructured":"Khanam R, Faiman B, Batool S, Najmuddin MM, Usman R, Kuriakose K, et al. Management of adverse reactions for BCMA-directed therapy in relapsed multiple myeloma: a focused review. J Clin Med. 2023;12(17):5539. https:\/\/doi.org\/10.3390\/jcm12175539.","journal-title":"J Clin Med"},{"issue":"3","key":"1122_CR189","doi-asserted-by":"publisher","first-page":"906","DOI":"10.3324\/haematol.2023.283590","volume":"109","author":"L Hammons","year":"2024","unstructured":"Hammons L, Szabo A, Janardan A, Bhatlapenumarthi V, Annyapu E, Dhakal B, et al. The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (BsAb) therapy in patients with relapsed refractory multiple myeloma. Haematologica. 2024;109(3):906\u201314. https:\/\/doi.org\/10.3324\/haematol.2023.283590.","journal-title":"Haematologica"},{"issue":"3","key":"1122_CR190","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1002\/JHA2.729","volume":"4","author":"C O\u2019Neill","year":"2023","unstructured":"O\u2019Neill C, van de Donk NJ, et al. T-cell redirecting bispecific antibodies in multiple myeloma: current landscape and future directions. EJHaem. 2023;4(3):811\u201322. https:\/\/doi.org\/10.1002\/JHA2.729.","journal-title":"EJHaem"},{"issue":"31","key":"1122_CR191","doi-asserted-by":"publisher","first-page":"3576","DOI":"10.1200\/JCO.22.01504","volume":"40","author":"A D\u2019Souza","year":"2022","unstructured":"D\u2019Souza A, Shah N, Rodriguez C, Voorhees PM, Weisel K, Bueno OF, et al. A phase I first-in-human study of ABBV-383, a B-cell maturation antigen \u00d7 CD3 bispecific T-cell redirecting antibody, in patients with relapsed\/refractory multiple myeloma. J Clin Oncol. 2022;40(31):3576\u201386. https:\/\/doi.org\/10.1200\/JCO.22.01504.","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"1122_CR192","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000967700.16100.68","volume":"7","author":"HC Lee","year":"2023","unstructured":"Lee HC, Bumma N, Richter J, Dhodapkar M, Hoffman JE, Suvannasankha A, Zonder J, et al. LINKER-MM1 study: linvoseltamab (REGN5458) in patients with relapsed\/refractory multiple myeloma. Hemasphere. 2023;7(Suppl): e1610068. https:\/\/doi.org\/10.1097\/01.HS9.0000967700.16100.68.","journal-title":"Hemasphere."},{"issue":"7","key":"1122_CR193","doi-asserted-by":"publisher","first-page":"CT001","DOI":"10.1158\/1538-7445.AM2024-CT001","volume":"84","author":"S Jagannath","year":"2024","unstructured":"Jagannath S, Richter J, Dhodapkar MV, Hoffman JE, Lee HC, Suvannasankha A, et al. Abstract CT001: Linvoseltamab, a B-cell maturation antigen-targeted T-cell-engaging bispecific antibody, induces deep and durable responses in patients with relapsed or refractory multiple myeloma including difficult-to-treat subgroups. Cancer Res. 2024;84(7):CT001. https:\/\/doi.org\/10.1158\/1538-7445.AM2024-CT001.","journal-title":"Cancer Res"},{"issue":"22","key":"1122_CR194","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1200\/JCO.24.01008","volume":"42","author":"N Bumma","year":"2024","unstructured":"Bumma N, Richter J, Jagannath S, Lee HC, Hoffman JE, Suvannasankha A, et al. Linvoseltamab for treatment of relapsed\/refractory multiple myeloma. J Clin Oncol. 2024;42(22):2702\u201312. https:\/\/doi.org\/10.1200\/JCO.24.01008.","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"1122_CR195","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000970436.12207.45","volume":"7","author":"SW Wong","year":"2023","unstructured":"Wong SW, Bar N, Mateos MV, Ribas P, Hansson M, Paris L, et al. P883: alnuctamab (alnuc; BMS-986349; cc-93269), a BCMA \u00d7 CD3 T-cell engager, in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): latest results from a phase 1 first-in-human clinical study. Hemasphere. 2023;7(Suppl): e1220745. https:\/\/doi.org\/10.1097\/01.HS9.0000970436.12207.45.","journal-title":"Hemasphere."},{"issue":"8","key":"1122_CR196","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1200\/JCO.19.02657","volume":"38","author":"MS Topp","year":"2020","unstructured":"Topp MS, Duell J, Zugmaier G, Attal M, Moreau P, Langer C, et al. Anti-B-cell maturation antigen BiTE molecule AMG 420 induces responses in multiple myeloma. J Clin Oncol. 2020;38(8):775\u201383. https:\/\/doi.org\/10.1200\/JCO.19.02657.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1122_CR197","doi-asserted-by":"publisher","first-page":"164","DOI":"10.46883\/2023.25920991","volume":"37","author":"ZJ Gahvari","year":"2023","unstructured":"Gahvari ZJ, Callander NS. The management of relapsed and refractory multiple myeloma. Oncology (Williston Park). 2023;37(4):164\u201374. https:\/\/doi.org\/10.46883\/2023.25920991.","journal-title":"Oncology (Williston Park)"},{"issue":"3","key":"1122_CR198","doi-asserted-by":"publisher","first-page":"252","DOI":"10.6004\/jadpro.2023.14.3.14","volume":"14","author":"C Rodriguez","year":"2023","unstructured":"Rodriguez C, Catamero D. Novel treatments for patients with relapsed\/refractory multiple myeloma. J Adv Pract Oncol. 2023;14(3):252\u20136. https:\/\/doi.org\/10.6004\/jadpro.2023.14.3.14.","journal-title":"J Adv Pract Oncol"},{"issue":"3","key":"1122_CR199","doi-asserted-by":"publisher","first-page":"615","DOI":"10.3109\/10428194.2014.924117","volume":"56","author":"KM Sanfilippo","year":"2015","unstructured":"Sanfilippo KM, Gage B, Luo S, Weilbaecher K, Tomasson M, Vij R, et al. Comparative effectiveness on survival of zoledronic acid versus pamidronate in multiple myeloma. Leuk Lymphoma. 2015;56(3):615\u201321. https:\/\/doi.org\/10.3109\/10428194.2014.924117.","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"1122_CR200","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jbo.2013.12.001","volume":"3","author":"J Zekri","year":"2014","unstructured":"Zekri J, Mansour M, Karim SM. The anti-tumour effects of zoledronic acid. J Bone Oncol. 2014;3(1):25\u201335. https:\/\/doi.org\/10.1016\/j.jbo.2013.12.001.","journal-title":"J Bone Oncol."},{"issue":"10","key":"1122_CR201","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.clml.2023.05.008","volume":"23","author":"S Giralt","year":"2023","unstructured":"Giralt S, Jolles S, Kerre T, Lazarus HM, Mustafa SS, Papanicolaou GA, et al. Recommendations for management of secondary antibody deficiency in multiple myeloma. Clin Lymphoma Myeloma Leuk. 2023;23(10):719\u201372. https:\/\/doi.org\/10.1016\/j.clml.2023.05.008.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"1122_CR202","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.clml.2020.12.026","volume":"21","author":"G Lancman","year":"2021","unstructured":"Lancman G, Lozada K, Athar N, Jacobs S, Doucette J, Cho HJ, et al. Efficacy of intravenous immunoglobulin for preventing infections in patients with multiple myeloma. Clin Lymphoma Myeloma Leuk. 2021;21(5):470\u20136. https:\/\/doi.org\/10.1016\/j.clml.2020.12.026.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"Supplement 1","key":"1122_CR203","doi-asserted-by":"publisher","first-page":"5415","DOI":"10.1182\/blood.V130.Suppl_1.5415.5415","volume":"130","author":"Y Alkhatib","year":"2017","unstructured":"Alkhatib Y, Dadla A, Malik D, Abdel-Rahman Z, Kuriakose P, Dabak VS, et al. Plasmapheresis and myeloma cast nephropathy: a meta-analysis of the available evidence. Blood. 2017;130(Supplement 1):5415. https:\/\/doi.org\/10.1182\/blood.V130.Suppl_1.5415.5415.","journal-title":"Blood"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-024-01122-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-024-01122-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-024-01122-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T22:07:46Z","timestamp":1743026866000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-024-01122-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,29]]},"references-count":203,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["1122"],"URL":"https:\/\/doi.org\/10.1007\/s11523-024-01122-4","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,29]]},"assertion":[{"value":"15 December 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external funding was used in the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"SM, AES, JM,\u00a0and JRB have no conflicts of interest to declare that might be relevant to the contents of the manuscript. James R. Berenson is an editorial board member of\n                      Targeted Oncology\n                      and was not involved in the selection of peer reviewers for the manuscript or any of the subsequent editorial decisions.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"SM, AES, and JRB wrote the manuscript.\u00a0JM provided the figures and substantial editorial review.\u00a0","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}